OraSure Technologies (NASDAQ:OSUR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research report released on Monday.

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Stock Down 3.4%

NASDAQ:OSUR opened at $3.75 on Monday. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58. The stock’s 50-day simple moving average is $4.16 and its 200 day simple moving average is $3.46. The firm has a market capitalization of $258.64 million, a PE ratio of -5.43 and a beta of 1.00.

Hedge Funds Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of OSUR. Nierenberg Investment Management Company LLC bought a new position in OraSure Technologies in the second quarter valued at about $247,775,000. Diversify Advisory Services LLC bought a new stake in shares of OraSure Technologies during the second quarter worth about $47,000. BlackRock Inc. bought a new stake in shares of OraSure Technologies during the second quarter worth about $27,905,000. Deutsche Bank AG acquired a new position in shares of OraSure Technologies in the second quarter valued at approximately $527,000. Finally, OneDigital Investment Advisors LLC acquired a new position in shares of OraSure Technologies in the second quarter valued at approximately $91,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.